Table 1 Baseline characteristics
Patient Characteristics | All patients (n=20) | CVE (n=10) | Controls (n=10) |
|---|---|---|---|
Demographics | |||
Age, years, mean (sd) | 63,3± 11,3 | 63,4± 11,9 | 63,1± 11,8 |
Woman no (%) | 10 (50%) | 5 (50%) | 5 (50%) |
RA disease characteristics | Â | Â | Â |
Disease duration, months | 11,2 (7,5-16,7) | 9,7 (5,7-16,1) | 15,7 (8,5-16,4) |
RF positive, n (%) | 16 (80%) | 8 (80%) | 8 (80%) |
ACPA positive, n (%) | 16 (80%) | 8 (80%) | 8 (80%) |
NSAID | 7 (35%) | 4 (40%) | 3 (30%) |
csDMARD | 19 (95%) | 10 (100%) | 9 (90%) |
bDMARD | 19 (95%) | 9 (90%) | 10 (100%) |
CV Risk factors | Â | Â | Â |
Hypertension | 10 (50%) | 5 (50%) | 5 (50%) |
Antihypertensive agents | 10 (50%) | 5 (50%) | 5 (50%) |
Dyslipidaemia | 6 (30%) | 5 (50%) | 1 (10%) |
 Statins | 6 (30%) | 5 (50%) | 1 (10%) |
Diabetus mellitus | 3 (10%) | 0 (0%) | 2 (20%) |
 Antidiabetics | 1 (5%) | 0 (0%) | 1 (10%) |
Platelet aggregation inhibitors | 15 (75%) | 10(100%) | 5 (50%) |
Dual antiplatelet therapy (acetylsalicylic acid AND P2Y12 inhibitor) | 10(50%) | 10(100%) | 0(0%) |